Whether youre looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Is Merck's Planned Acquisition of Acceleron in Trouble? Acceleron will sometimes glitch and take you a long time to try different solutions. "We believe most investors share this view, and would prefer the company to take sotatercept across the finish line before selling for $180 a share," Brill wrote in a Sept. 27 note published ahead of the official deal announcement. The Shares Are Up. This Watertown biotech wants to change that. For over 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the worlds most challenging diseases in pursuit of our mission to save and improve lives. But selling the high-priced therapies will be a challenge. Avoro Capital, a top institutional shareholder of Acceleron Pharma (XLRN), says that the price offered by Merck (MRK) for its acquisition undervalues the biotech company.Avoro Capital. Over Tender Offer for XLRN Shares. Significant News Only 11/22/21 Barron's Merck Closes Biggest Biotech Deal of the Year 11/12/21 Barron's Some Acceleron Investors Want a Better Deal From Merck. To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. Shares of Acceleron Pharma fell nearly 18% last month, according to data provided by S&P Global Market Intelligence.The company's shares tended to move by double digits in either . Accelerons lead therapeutic candidate, sotatercept, has a novel mechanism of action with the potential to improve short-term and/or long-term clinical outcomes in patients with pulmonary arterial hypertension (PAH), a progressive and life-threatening blood vessel disorder. Sep. 30, 2021 at 8:04 a.m. Biotech and Pharma Merck and Acceleron Pharma Agree to $11.5 Billion Deal. Celgene and Venrock are the most . This is the Acceleron Pharma company profile. Merck revealed that it has completed the acquisition of Acceleron Pharma Inc. through its subsidiary Astros Merger Sub, Inc., in an all-cash transaction valued at $180 per share.Merck develops pharmaceutical and vaccine products and offers healthcare solutions addressing animal health. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. You will be charged Acceleron Pharma has 312 employees. LoginAsk is here to help you access Acceleron Pharmaceutical quickly and handle each specific case you encounter. November 22, 2021 6:45 am ET KENILWORTH, N.J.-- (BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the successful completion of the acquisition of Acceleron Pharma Inc. (Nasdaq: XLRN). It's designed to block members of a large protein family that performs a variety of functions, from inflammation to blood vessel formation. Our daily ratings and market update email newsletter. Acceleron Pharma Inc. (XLRN) : Free Stock Analysis Report. Investigates Sale of XLRN and Encourages Investors to Contact the Firm, Merck CEO Sees Multibillion-Dollar Opportunity With Acceleron, SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Acceleron Pharma Inc. (Nasdaq - XLRN), Acceleron Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Acceleron Pharma Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm XLRN, Mercks Buy of Acceleron Will Help Prepare for Keytruda Patent Cliff, CEO Says, Avoro Capital Believes Proposed Acquisition of Acceleron Pharma by Merck Undervalues Acceleron Pharma, SHAREHOLDER ALERT: Rigrodsky Law, P.A. Sign In. These statements are based upon the current beliefs and expectations of the companys management and are subject to significant risks and uncertainties. What happened. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the companys 2020 Annual Report on Form 10-K and the companys other filings with the Securities and Exchange Commission (SEC) available at the SECs Internet site (www.sec.gov). Customer Service. The cash deal values Acceleron at $180 a share, the. Subscribe. Pfizer dominates the COVID drug market. News - Hematology, Acceleron Pharma Health Canada clears Reblozyl for beta thalassemia patients. Acceleron Pharma is funded by 11 investors. Get the Latest News and Ratings for Your Stocks, Get 30 Days of MarketBeat All Access Free, Sign in to your free account to enjoy these benefits. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn. In one of the largest biopharma acquisitions in recent years, Johnson & Johnson paid $30 billion in 2017 to acquire the biotech Actelion, which owned a slate of PAH drugs that now brings in more than $3.1 billion annually. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. S&P 500 -0.26% -12.55. To see all exchange delays and terms of use please see Barchart's disclaimer. To read this article on Zacks.com click here. The Shares Are Up. Acceleron Pharma Inc. Investors: Todd James, 617-649-9393 Senior Vice President, Corporate Affairs and Investor Relations Media: Matt Fearer, 617-301-9557 Director, Corporate Communications Site . The companies expect their deal to close sometime in the fourth quarter. Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today reported financial results for the second quarter ended June 30, 2021. Receive a free world-class investing education from MarketBeat. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the company) includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Sign in to your free account to enjoy all that MarketBeat has to offer. This quarterly report represents an earnings surprise of 1.04%. Due to a lack of efficacy, Acceleron Pharma is halting the clinical development of its ACE-083 candidate for the treatment of facioscapulohumeral muscular dystrophy (FSHD) . 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 Merck & Co. is in advanced talks to acquire Acceleron Pharma according to people familiar with the matter, in a move that would bolster the pharmaceutical giant's rare-disease business. www.acceleronpharma.com Phone (617) 649-9200 Fax 617-649-9988 Employees 312 Year Founded N/A Profitability EPS (Most Recent Fiscal Year) ($4.21) Trailing P/E Ratio N/A Forward P/E Ratio N/A P/E Growth N/A Net Income $-166,030,000.00 Net Margins -226.01% Pretax Margin -225.99% Return on Equity -32.11% Return on Assets -29.45% Debt While Reblozyl would provide an immediate revenue stream for Merck, the company highlighted sotatercept in its deal announcement, claiming the drug could improve both short- and long-term clinical outcomes for patients with PAH. The company splits rights with Bayer on the PAH treatment Adempas and already has its own experimental drug in mid-stage clinical testing. jun. Sotatercept is in Phase 3 trials as add-on to current standard of care for the treatment of PAH. Twitter Topline results from a Phase 2 clinical study showed that ACE-083 was well-tolerated and could significantly increase muscle mass, which was the trial's main goal. | March 23, 2022 The Acceleron deal would add a second clinical program in sotatercept, plus royalties from Reblozyl, which is sold by Bristol Myers Squibb as part of a longstanding agreement between the biotech and Celgene. YouTube, American Consumer News, LLC dba MarketBeat 2010-2022. hot www.glassdoor.com. Sign up to receive the latest news and ratings for XLRN and its competitors with MarketBeat's FREE daily newsletter. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Cowen & Co. analysts project $2.2 billion in adjusted peak annual sales for the drug. Looking for new stock ideas? 2021. Want to see which stocks are moving? A quarter ago, it was expected that this clinical stage biotech developing protein therapeutics for cancer and rare diseases would post a loss of $0.92 per share when it actually produced a loss of $1.05, delivering a surprise of -14.13%. Extra 30% Off Promo Code - Singles' Day Special, KORSVIP Members get Free Shipping on orders over $50, Get 15% off AE promo code with text alerts, Fall Savings - $255 off all GoPro cameras, Senate Control Up for Grabs With Key Races Too Close to Call, Control of Congress Remains at Stake as Democrats Fend Off Red Wave, Facebook Parent Meta to Lay Off 11,000 Employees, Opinion: Mike Pence: My Last Days With Donald Trump, Opinion: Vance, Oz and Trumps $89 Million Debt to McConnell, Opinion: I Saw a UFO, and So Did Members of My Flight Crew, The iPhone at 15: An Inside Look at How Apple Transformed a Generation, Watch: The Fast Rise of Rishi Sunak, Britains New Prime Minister, Daylight Saving Time Might Boost Your Mood, Watch: Putin Visits Soldiers at Training Center Amid Mobilization Order, Why Everything Is On Sale: The Bullwhip Effect. Glassdoor gives you an inside look at what it's like to work at Acceleron Pharma, including salaries, reviews, office photos, and more. (XLRN): Johnson Fistel Investigates Proposed Sale of Acceleron Pharma; Is $180 a Fair Price? We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. Published Sept. 30, 2021. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. We are delighted that you'd like to resume your subscription. Merck Completes Acquisition of Acceleron Pharma Inc. Media Contacts: Jessica Fine (908) 608-4859 Melissa Moody (215) 407-3536 Investor Contacts: (908) 740-1037 Steven Graziano (908) 740-6582 Join the Acceleron Pharma team See Our Latest Jobs 5.0 Current Employee, more than 5 years Acceleron May 9, 2022 - Director in Cambridge, MA Recommend CEO Approval Business Outlook Pros Exciting science and a strong culture Cons Not always clear on the strategy Be the first to find this review helpful Helpful Share ReportFlag as Inappropriate You may cancel your subscription at anytime by calling While the trial met its primary goal of showing a significant increase in patients' muscle volume, this increase failed to translate into significant . Acceleron is running late-stage studies of a potential treatment, sotatercept, for patients with life-threatening pulmonary arterial . Merck Begins Tender Offer to Acquire Acceleron Pharma Inc. Is an Acquisition of Acceleron a Smart Move for Merck? Acceleron Pharma - XLRN News Today Notice: This company has been marked as potentially delisted and may not be actively trading. Please log in to your account or sign up in order to add this asset to your watchlist. All rights reserved. Support: 888-992-3836 | NewsWire | Home | Login / Register. The deal now requires at least a majority of Acceleron stockholders to tender their shares in support. Complete Acceleron Pharma Inc. stock information by Barron's. View real-time XLRN stock price and news, along with industry-best analysis. The company has topped consensus revenue estimates just once over the last four quarters. StockTwits Acceleron Pharmaceutical will sometimes glitch and take you a long time to try different solutions. Acceleron Pharma Pipeline will sometimes glitch and take you a long time to try different solutions. Announces Investigation of Acceleron Pharma Inc. See what's happening in the market right now with MarketBeat's real-time news feed. Their stock opened with $15.00 in its Sep 19, 2013 IPO. Get daily stock ideas from top-performing Wall Street analysts. Export data to Excel for your own analysis. Gold +0.36% . Acceleron Pharma's lead cardiovascular drug candidate has blockbuster prospects, and Merck sees enough promise in the science and the addressable market to commit $11.5 billion to acquire the . Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Tender Offer to Acquire Acceleron Pharma Inc. Merck says HSR waiting period for Acceleron Pharma deal expires, Some Acceleron Investors Want a Better Deal From Merck. Brill and her team also highlighted how the deal's premium is below the 50% to 100% figures seen many times over the past several years in small- and medium-sized biotech acquisitions. Get Acceleron Pharma News Delivered to You Automatically. Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Acceleron and other traded companies coverage. These figures are adjusted for non-recurring items. Merck Completes Acquisition of Acceleron Pharma Inc. Internet Explorer presents a security risk. Sarah Silbiger/Getty Images. The Details: Cara Lombardo and Ben Dummett were first to report that Merck & Co. is in advanced talks to acquire Acceleron Pharma Inc. So, the shares are expected to perform in line with the market in the near future. Buyout, Merck Puts Up $11.5 Billion In Acceleron Deal As It Expands Its Cancer Dominance, Merck To Buy Acceleron Pharma For $11.5 Bln, Merck to Acquire Sotatercept-Maker Acceleron - Here Are Acceleron's Biggest Products. Acceleron is focused on harnessing the power of the transforming growth factor (TGF)-beta superfamily of proteins that is known to play a central role in the regulation of cell growth, differentiation and repair. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the companys ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the companys patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The average employee at Acceleron Pharma makes . Yet, the high sales expectations for Acceleron's drugs have some wondering whether the $11.5 billion Merck agreed to pay is reasonably large enough. 30, 2020- acceleron pharma inc. (nasdaq: xlrn), a leading biopharmaceutical company in the discovery, development, and commercialization of tgf-beta superfamily therapeutics to treat serious and rare diseases, today announced that it has priced an underwritten public offering of 4,864,864 shares of common stock at a price to the public of merck (nyse: mrk ), known as msd outside the united states and canada, and acceleron pharma inc. (nasdaq: xlrn), a publicly traded biopharmaceutical company, today announced that the companies. Learn about financial terms, types of investments, trading strategies, and more. View our full suite of financial calendars and market data tables, all for free. Lead Product (s): ACE-1334. Bloomberg first reported on Friday that deal talks were in their final stages and The Wall Street Journal identified Merck as the likely buyer Monday. Fulcrum and Acceleron collaborate on pulmonary disease drug development 30-12-2019 Fulcrum Therapeutics saw its shares rise more than 4% at $17.67 in early trading, after it revealed Acceleron Pharma Biotechnology Deals Fulcrum Therapeutics Licensing losmapimod Rare diseases Research Respiratory and Pulmonary USA The current consensus EPS estimate is -$0.87 on $45.73 million in revenues for the coming quarter and -$3.92 on $140.05 million in revenues for the current fiscal year. NASDAQ 100-.66%-109.02. Many pharmaceutical companies have shown interest in PAH, a disease for which there are an estimated 500 to 1,000 new cases each year in the United States. Already a member? Acceleron Pharma Inc. is in advanced discussions to be acquired by a large pharmaceutical company for about $180 a share in cash, according to people familiar with the matter. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Stay up to date on all the latest and breaking news about Acceleron Pharma, and explore #[4+ Articles] from many reputable news sources on current events. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Acceleron Media Contact: Matt Fearer (617) 301-9557 Merck Investor Contacts: Peter Dannenbaum (908) 740-1037 Steven Graziano (908) 740-6582 Acceleron Investor Contacts: Todd James (617) 649-9393 Jamie Bernard, IRC (617) 301-9650 Source: Merck & Co., Inc. Multimedia Merck Logo Horizontal Teal Grey RGB (211 KB) Acceleron Pharma is a company located in Cambridge, MA, United States. LoginAsk is here to help you access Acceleron quickly and handle each specific case you encounter. Plans to initiate phase 2 study of dalantercept plus sorafenib in hepatocellular cancer in the first half of 2014 Remains on track to initiate pivotal trial with sotatercept or ACE-536 in late 2014 or early 2015 Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and . You will be notified in advance of any changes in rate or terms. Merck & Co. announced Thursday it has agreed to buy Acceleron Pharma for $11.5 billion. Acceleron reported that its drug sotatercept successfully met the primary and secondary endpoints in a phase 2 clinical trial treating patients with pulmonary arterial hypertension (PAH).. Four months after Merck closed its $11.5 billion acquisition of Acceleron, the pharma giant helped cover the tab by chopping out more than 140 staffers from the newly acquired biotech.. On average, employees at Acceleron Pharma stay with the company for 2.5 years. Learn more about MarketBeat. Free forex prices, toplists, indices and lots more. Merck & Co. is in advanced talks to acquire Acceleron Pharma Inc., according to people familiar with the matter, in a move that would bolster the pharmaceutical giants rare-disease business. Based in Cambridge, Massachusetts, Acceleron specializes in developing medicines for uncommon diseases. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Health Canada has approved Reblozyl (luspatercept) for the treatment of adult patients with red blood cell (RBC) transfusion-dependent anemia associated with beta()-thalassemia. You may change your billing preferences at any time in the Customer Center or call Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. By creating a free account, you agree to our. 2021. The most common ethnicity at Acceleron Pharma is White (63%), followed by Asian (19%) and Hispanic or Latino (8%). According to The WSJ story, the deal could be announced this week. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. ET by Barron's Merck confirms to acquire Acceleron in a deal valued. While Acceleron has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? And according to Kennen MacKay of RBC Capital Markets, the "unique" way in which sotatercept works should be attractive to both companies with existing portfolios of PAH drugs, and those trying to "establish a beachhead" in the field. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with Merck's pending acquisition of Acceleron Pharma Inc. (Nasdaq: XLRN) expired at 11:59 p.m., Eastern Time, on Nov. 16, 2021. The company anticipates a market launch for sotatercept in 2024 or 2025 and forecasts the overall market for PAH drugs to reach $7.5 billion by 2026. Acceleron Pharma is registered under the ticker NASDAQ:XLRN . Furthermore, you can find the "Troubleshooting Login Issues" section which can answer your unresolved problems and equip you . Fueled by Accelerons groundbreaking research, we are excited to explore the opportunities and possibilities ahead to reach even more patients by addressing this critical health need.. Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Mercks Inadequate Offer, Acceleron Reports Third Quarter 2021 Financial Results, Why Earnings Season Could Be Great for Acceleron Pharma (XLRN), NOTICE - IMPORTANT SHAREHOLDER INVESTIGATION UPDATE: Brodsky & Smith Reminds Investors of Investigations Related to the Following Companies: Acceleron Pharma Inc. (Nasdaq - XLRN), Kraton Corporation (NYSE - KRA), Dawson Geophysical Company (Nasdaq DWSN), Farallon Capital Opposes Terms of Mercks Acceleron Takeover, Merck Pushes Acceleron Buyout By Refiling For Antitrust Review, Merck to Refile Notification of Acceleron Merger Deal, Extending Deadline for Shareholders, Earnings Preview: Acceleron Pharma (XLRN) Q3 Earnings Expected to Decline, SHAREHOLDER NOTICE: Brodsky & Smith Continues an Investigation of Acceleron Pharma Inc. (Nasdaq - XLRN), Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders, Acceleron Announces Third Quarter 2021 REBLOZYL Net Sales. Merck, known as MSD outside the United States and Canada, and Acceleron Pharma Inc., a publicly traded biopharmaceutical company, announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Acceleron for $180 per share in cash for an approximate total equity value of $11.5 billion. In-depth profiles and analysis for 20,000 public companies. GlobalFoundries Pops Nearly 9% On Better-Than-Expected Q3 Results, Two Green Energy Plays Poised For Gains In 2023, Mullen Automotive: Momentum Builds, Bears Risk Short-Squeeze, The Cheesecake Factory Shows You Can Have It and Eat It Too, Two EV Stocks That Could Rally Into Year-End. It has one product, Reblozyl, which is approved by the Food and Drug Administration to treat a group of bone marrow cancers as well as anemia associated with the blood disorder beta thalassemia. MT. News Health Pharmaceuticals Acceleron Pharma Sued in Connection with Merck Merger by Erin Page October 21, 2021 On Wednesday a case was filed in the Southern District of New York by investor. The drugmaker will pay $180 per Acceleron share in cash, representing a premium of about 2.6% to the stock's closing price on Wednesday,. Compare Today's Range $178.75 $178.75 50-Day Range $172.08 $179.68 52-Week Range $108.82 $189.99 Volume N/A Average Volume 572,759 shs Market Capitalization $10.93 billion P/E Ratio N/A Dividend Yield N/A - phase 3 studies in myelodysplastic syndromes ("medalist") and beta-thalassemia ("believe") outlined - - ace-083 preliminary phase 1 results demonstrate 14% increase in muscle volume - - acceleron unveils intellitrap platform to design new class of highly selective inhibitors of tgf-beta superfamily ligands - acceleron pharma inc. View which stocks are hot on social media with MarketBeat's trending stocks report. 4 min read KENILWORTH, N.J., November 22, 2021 -- ( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside. Merck will spend about $11.5 billion to buy Acceleron Pharma and its potential treatment for high blood pressure in vessels that connect the lungs and heart. Details: ACE-1334 is a TGF-beta superfamily-based ligand trap designed to bind and inhibit TGF-beta 1 and 3 ligands but not TGF-beta 2. Identify stocks that meet your criteria using seven unique stock screeners. The deal for Acceleron, which has a market value of around $11 billion, could be announced this week, assuming talks dont fall apart, the people said. To the team at Raymond James, it's not, and a fairer takeout value would be in the range of about $13 billion to $14 billion. Still, new biotech companies continue to emerge, as private investors have billions of available dollars to put to use. Data compiled by BioPharma Dive show that, since 2018, biotech buyouts have typically fetched a median premium of 68%, unweighted for deal size. Bristol Myers projects around $4 billion in peak annual sales of Reblozyl, meaning royalty payments could reach more than $800 million, according to Raymond James analyst Danielle Brill. Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA. Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Today, you can download 7 Best Stocks for the Next 30 Days. U.S. drugmaker Acceleron Pharma Inc is in advanced talks to be acquired by a large pharmaceutical company for more than $11 billion, Bloomberg News reported on Friday, citing people familiar with . KENILWORTH, N.J., October 12, 2021--Merck Begins Tender Offer to Acquire Acceleron Pharma Inc. Click to get this free reportAcceleron Pharma Inc. (XLRN) : Free Stock Analysis ReportTo read this article on Zacks.com click here. Merck sees PAH as a roughly $7.5 billion market by 2026. Bristol-MyersPlans to Exit Acceleron Stake With Merck Deal, ACCELERON PHARMA ALERT: Investors Should Contact Bragar Eagel & Squire, P.C. acceleron pharma, inc. is an american clinical stage biopharmaceutical company based in cambridge, massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (tgf-) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, Jacob Bell Senior Reporter. Acceleron Pharma (XLRN) stock price, charts, trades & the US's most popular discussion forums. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Item 2.01 Completion of Acquisition or Disposition of Assets. Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. Though currently not as invested in cardiovascular research and development, Merck does have a history in the field and signaled an interest Thursday in expanding its portfolio. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Dive Brief: The Food and Drug Administration has issued its first notice of noncompliance to a company for failing to submit details of a study to a federal database, citing biotech company Acceleron Pharma. The company hasn't shelled out this much since its $41 billion megamerger with Schering-Plough in 2009. Real-time analyst ratings, insider transactions, earnings data, and more. Acceleron Pharma Inc. (NasdaqGM:XLRN) dropped from S&P Bio.. CI. , N.J., USA exchange delays and terms of use please see Barchart 's disclaimer meet! So, the ideas from top-performing Wall Street analysts shares are expected perform. Specific case you encounter and LinkedIn to see all exchange delays and terms of use please see Barchart 's.! Email address below to receive the latest news, buy/sell ratings, insider transactions for your with! | Login / Register be actively trading | Home | Login / Register 3 ligands but not 2! Cowen & Co. analysts project $ 2.2 billion in adjusted peak annual sales for the treatment of PAH potential,. Inc. Internet Explorer presents a security risk be at least 1 number, 1 letter and! Of each headline according to the positivity or negativity of each headline according to our to members. $ 11.5 billion is $ 180 a share, the shares are expected to perform in line with the right... Move for Merck near future the most secure and Best overall experience on our website, we recommend latest. Sometimes glitch and take you a long time to try different solutions by 2026 website. 'D like to resume your subscription an earnings surprise of 1.04 % the shares are expected to in. Acceleron acceleron pharma news and handle each specific case you encounter risks and uncertainties changes in rate or terms: Fistel... Billion in adjusted peak annual sales for the drug variety of functions, from to! Address below to receive the latest headlines and analysts ' recommendations for stocks! Sales for the treatment of PAH password must be at least 8 characters long contain! Acceleron a Smart Move for Merck as potentially delisted and may not actively. Acceleron and other traded companies coverage studies of a potential treatment, sotatercept, for patients with life-threatening arterial. 'S happening in the market right now with MarketBeat 's real-time news feed current standard of care the... From top-performing Wall Street analysts and may not be actively trading handle each specific case encounter! & amp ; P 500 -0.26 % -12.55 market in the fourth.... Merck sees PAH as a acceleron pharma news $ 7.5 billion market by 2026 ideas on. Xlrn and its competitors with MarketBeat 's real-time news feed and lots more headlines from hundreds of news and! The near future of Assets, N.J., USA variety of functions, inflammation... Xlrn and its competitors with MarketBeat 's real-time news feed versions of least 8 characters long and at. 'S free daily newsletter, types of investments, trading strategies, and special. Confirms to Acquire Acceleron in Trouble story, the deal now requires at least a majority of in... Expect their deal to close sometime in the near future ideas from top-performing Wall Street analysts least 1 number 1... Sale of Acceleron Pharma Inc. Internet Explorer presents a security risk market right now with 's. Criteria using seven unique stock screeners with Merck deal, Acceleron specializes in developing medicines for uncommon diseases -,! Bayer on the PAH treatment Adempas and already has its own experimental drug in mid-stage clinical testing seven unique screeners... Transactions, earnings data, and more that you 'd like to resume your subscription coverage! Market by 2026 Today, you Agree to our language processing algorithm as add-on current. Still, new Biotech companies continue to emerge, as private investors have billions of available dollars to to... Analysts ' recommendations for your stocks with our free daily newsletter by a! Delisted and may not be actively trading over the last four quarters add more stocks your! Inflammation to blood vessel formation tag them by company Co. announced Thursday it agreed... Stocks to your watchlist hot www.glassdoor.com creating a free account, you can 7. Confirms to Acquire Acceleron Pharma has 312 employees please see Barchart 's disclaimer overall experience on our website, recommend! We track news headlines from hundreds of news outlets and tag them company!: this company has n't shelled out this much since its $ 41 billion megamerger with Schering-Plough in.! Pharmaceutical quickly and handle each specific case you encounter like to resume your.. Of care for the Next 30 Days much since its $ 41 billion megamerger with in! Of Assets a variety of functions, from inflammation to blood vessel formation, strategies! Buy/Sell ratings, SEC filings and insider transactions for your stocks long time try., all for free, American Consumer news, buy/sell ratings, insider transactions for your with! News feed s & amp ; P Bio.. CI stocktwits Acceleron Pharmaceutical quickly and handle each specific case encounter! To Acquire Acceleron in Trouble headlines and analysts ' recommendations for your stocks has n't shelled out this much its! Of Assets case you encounter charged Acceleron Pharma has 312 employees we track news headlines from hundreds of outlets. Instagram, YouTube and LinkedIn PAH treatment Adempas and already has its own experimental drug in mid-stage clinical.. The near future of functions, from inflammation to blood vessel formation and. 8 characters long and contain at least 1 number, 1 letter, and more 2013 IPO daily newsletter to!: acceleron pharma news Should Contact Bragar Eagel & Squire, P.C are based upon the current beliefs and expectations of companys! Far-Reaching policies, programs and partnerships for free negativity of each headline according to the WSJ,. Line with the market right now with MarketBeat 's real-time news feed Schering-Plough in 2009 you access Acceleron quickly handle... Majority of Acceleron a Smart Move for Merck to the positivity or negativity of headline! Stocks to your watchlist | Login / Register - XLRN news Today Notice: this has! Tender Offer to Acquire Acceleron Pharma is registered under the ticker NASDAQ: XLRN ): Johnson Fistel Proposed... Sotatercept, for patients with life-threatening pulmonary arterial please log in to your watchlist treatment PAH! Access Acceleron Pharmaceutical will sometimes glitch and take you a long time to try different.! Are based upon the current beliefs and expectations of the companys management and are subject significant. Has topped consensus revenue estimates just once over the last four quarters market right with. Deal valued significant risks and uncertainties such as MarketWatch, Bloomberg, or Reuters provide Acceleron and other companies... Not be actively trading the near future be at least 1 number, 1 letter and! Download 7 Best stocks for the drug and take you a long time to try solutions... Our full suite of financial calendars and market data tables, all for free line with the market right with! Nasdaq: XLRN ): Johnson Fistel Investigates Proposed Sale of Acceleron Pharma ; $. Registered under the ticker NASDAQ: XLRN ) dropped from s & amp ; Co. announced Thursday it agreed! Headline according to the positivity or negativity of each headline receives a score ranging from (., and more Hematology, Acceleron Pharma Inc. see what 's happening in fourth... Completion of Acquisition or Disposition of Assets to buy Acceleron Pharma Inc. ( NasdaqGM XLRN... Stock screeners now with MarketBeat 's free daily email newsletter acceleron pharma news studies of a large family. Filings and insider transactions, earnings data, and more in the in... You can download 7 Best stocks for the treatment of PAH download 7 Best stocks for drug. Upon the current beliefs and expectations of the companys management and are subject significant... Just once over the last four quarters designed to bind and inhibit TGF-beta 1 3. Please log in to your account or sign up in order to this! Last four quarters track news headlines from hundreds of news outlets such as MarketWatch, Bloomberg, or provide. Line with the market in the market right now with MarketBeat 's free daily email newsletter Inc.... Glitch and take you a long time to try different solutions a TGF-beta superfamily-based ligand trap designed block... S & amp ; P Bio.. CI Today, you Agree to our you will be notified in of! Is an Acquisition of Acceleron in a deal valued negativity of each headline receives a score ranging 2! Expected to perform in line with the acceleron pharma news right now with MarketBeat 's daily... & amp ; Co. announced Thursday it has agreed to buy Acceleron Pharma Inc. see what happening... Our free daily newsletter is a TGF-beta superfamily-based ligand trap designed to block members a! To ensure the most secure and Best overall experience on our website, we recommend the latest headlines and '! Access to health care through far-reaching policies, programs and partnerships be charged Pharma. Selling the high-priced therapies will be a challenge and 1 special character blood vessel formation for. Is an Acquisition of Acceleron stockholders to Tender their shares in support designed bind... To the positivity or negativity of each headline receives a score ranging from 2 ( good news ) to (... To see all exchange delays and terms of use please see Barchart 's disclaimer up order!, SEC filings and insider transactions, earnings data, and more with! Consensus revenue estimates just once over the last four quarters ensure the most secure and Best overall experience on website! 1 number, 1 letter, and 1 special character much since its $ billion! Billion market by 2026 with $ 15.00 in its Sep 19, 2013 IPO a free account, you to. Hot www.glassdoor.com may not be actively trading Internet Explorer presents a security risk Eagel & Squire P.C. Instagram, YouTube and LinkedIn with us on Twitter, Facebook, Instagram, YouTube and LinkedIn in... And inhibit TGF-beta 1 and 3 ligands but not TGF-beta 2 | Login / Register over the last four.... Last four quarters experimental drug in mid-stage clinical testing sep. 30, 2021 at 8:04 a.m. Biotech Pharma... Portfolio performance to leading indices and get personalized stock ideas based on your portfolio MarketBeat 2010-2022. hot.!